Becton, Dickinson and Company (NYSE:BDX – Get Free Report) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Wednesday, Zacks reports.
Other equities research analysts have also issued reports about the stock. Jefferies Financial Group reiterated a “buy” rating and issued a $210.00 target price on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Wells Fargo & Company boosted their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Barclays began coverage on Becton, Dickinson and Company in a research report on Wednesday, October 7th. They set an “underweight” rating and a $165.00 price target for the company. Evercore set a $180.00 price objective on shares of Becton, Dickinson and Company in a research report on Monday, July 6th. Finally, UBS Group assumed coverage on Becton, Dickinson and Company in a report on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $185.07.
Get Our Latest Stock Analysis on BDX
Becton, Dickinson and Company Stock Up 3.0%
Shares of BDX opened at $200.21 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The company has a market capitalization of $55.16 billion, a P/E ratio of 60.30, a PEG ratio of 13.10 and a beta of 0.21. The business’s 50 day simple moving average is $185.10 and its 200-day simple moving average is $164.86. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $200.47.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. Becton, Dickinson and Company’s revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.
Insider Buying and Selling at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, CEO Thomas Polen, Jr. sold 4,152 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at $20,380,155. This represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 6,906 shares of company stock worth $1,265,855 over the last three months. Corporate insiders own 0.40% of the company’s stock.
Institutional Investors Weigh In On Becton, Dickinson and Company
Hedge funds have recently modified their holdings of the company. Capital Investment Advisors LLC raised its position in Becton, Dickinson and Company by 40.4% in the third quarter. Capital Investment Advisors LLC now owns 2,262 shares of the medical instruments supplier’s stock valued at $405,000 after purchasing an additional 651 shares during the last quarter. Wedbush Securities Inc. boosted its stake in shares of Becton, Dickinson and Company by 16.8% during the third quarter. Wedbush Securities Inc. now owns 17,424 shares of the medical instruments supplier’s stock valued at $3,119,000 after purchasing an additional 2,512 shares in the last quarter. Sterling Capital Management LLC boosted its stake in shares of Becton, Dickinson and Company by 16.8% during the third quarter. Sterling Capital Management LLC now owns 10,167 shares of the medical instruments supplier’s stock valued at $1,820,000 after purchasing an additional 1,459 shares in the last quarter. Yousif Capital Management LLC grew its holdings in shares of Becton, Dickinson and Company by 19.3% during the third quarter. Yousif Capital Management LLC now owns 69,438 shares of the medical instruments supplier’s stock worth $12,429,000 after purchasing an additional 11,257 shares during the last quarter. Finally, Patrick M Sweeney & Associates Inc. bought a new stake in shares of Becton, Dickinson and Company during the third quarter worth about $233,000. Institutional investors and hedge funds own 86.97% of the company’s stock.
Becton, Dickinson and Company Company Profile
Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.
BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.
Read More
- Five stocks we like better than Becton, Dickinson and Company
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
- Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
- Tesla’s Flying-Car Hype Hits an Earnings Reality Check
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
